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The phosphorylation of eukaryotic translation initiation factor 2 alpha (eIF2) is activated in response to 
various stresses such as viral infection, nutrient deprivation, and stress to the endoplasmic reticulum. Severe 
stress to the endoplasmic reticulum, for instance, induces an apoptotic pathway, while mild stress, on the 
contrary, leads to a pro-survival pathway. Little has been known about the elaborate role of eIF2 
phosphorylation in the development of bone-forming osteoblasts and bone-resorbing osteoclasts. Using 
salubrinal and guanabenz as inhibitors of the de-phosphorylation of eIF2, we have recently reported that the 
phosphorylation of eIF2 significantly alters fates of both osteoblasts and osteoclasts. Based on our recent 
findings, we review in this research highlight the potential mechanisms of the enhancement of osteoblastogenesis 
and the suppression of osteoclastogenesis through the elevated level of phosphorylated eIF2. 
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Mechanism of the enhancement of osteoblastogenesis by 
the inhibition of de-phosphorylation of eIF2 
Bone remodeling is a combined process of bone formation 
by osteoblasts and bone resorption by osteoclasts.  We first 
examined the involvement of eIF2 in regulation of 
osteoblasts. Stress to the endoplasmic reticulum leads to the 
elevated phosphorylation level of eIF2 and suppresses 
general translation initiation except for some 
stress-responsive genes, including activating transcription 
factor 4 (ATF4) [1, 2]. ATF4 is an important transcription 
factor for differentiation of mature osteoblasts [3], prompting 
a question: Does the inhibition of de-phosphorylation of 
eIF2 stimulate development of osteoblasts? Salubrinal and 
guanabenz are synthetic chemical agents known to 
specifically de-phosphorylate eIF2 by inhibiting protein 
phosphatase 1 (PP1) [4, 5]. They are also known as 
suppressors of stress to the endoplasmic reticulum.  
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In response to salubrinal and guanabenz, the level of 
phosphorylation of eIF2 was elevated in MC3T3 E1 
osteoblast-like cells. These agents also increased the level of 
ATF4 as well as osteocalcin, which is known as a marker for 
osteoblastogenesis[6,7]. Furthermore, the process of 
mineralization is enhanced. Thus, the inhibition of 
de-phosphorylation of eIF2a by salubrinal and guanabenz 
enhances development and mineralization of osteoblasts. 
Mechanism of the suppression of osteoclastogenesis by 
the inhibition of de-phosphorylation of eIF2 
We next investigated the involvement of eIF2 in 
regulation of bone-resorbing osteoclasts. In RAW264.7 cells 
and mouse primary macrophages, treatment with receptor 
activator of nuclear factor kappa-B (RANKL) stimulate their 
development to mature osteoclasts. However, the 
administration of salubrinal and guanabenz decreased the 
number of tartrate-resistant acid phosphatase (TRAP) 
positive cells and suppressed osteoclastogenesis[6-9]. As a 
mechanism for the observed suppression of 
osteoclastogenesis, it was reported that these synthetic agents 
reduced the level of RANKL-induced activation of nuclear 
factor of activated T-cells, cytoplasmic 1 (NFATc1)[6,7], 
which is a master transcription factor of osteoclastogenesis 
[10]. In order to identify transcription factor(s) that 
downregulated NFATc1, genome-wide microarray analysis 
was performed. 
Principal component analysis (PCA) is a statistical 
procedure used to reduce the dimensions of a large dataset to 
help identify axes that best explain the variance of the data 
[11].  PCA can be used to analyze genome-wide microarray 
data and identify principal axes and genes that highly 
contribute to those axes.  PCA predicted a set of stimulatory 
and inhibitory transcription factor candidates underlying 
salubrinal- and guanabenz-driven suppression of 
osteoclastogenesis. Among these, two AP-1 transcription 
factors (c-Fos and JunB) were included. 
As predicted, expression levels of c-Fos and JunB were 
upregulated by RANKL, and their upregulation was 
suppressed by salubrinal and guanabenz in mouse primary 
macrophage and RAW264.7 cells [9]. In RAW264.7 cells, a 
partial silencing of c-Fos by RNA interference attenuated 
RANKL-driven expression of NFATc1, TRAP, and 
cathepsin K. A partial silencing of JunB reduced NFATc1 
and TRAP, but not cathepsin K. To further analyze 
regulatory linkages among NFATc1, c-Fos and JunB, a 
partial silencing of NFATc1 was conducted.  Twelve hours 
after RANKL treatment in RAW264.7 cells, treatment with 
NFATc1 siRNA did not alter expression of c-Fos and JunB.  
In 24 h, however, the level of c-Fos was significantly 
reduced without affecting the level of JunB[9]. Collectively, 
the result suggests a potential feedback loop between 
NFATc1 and c-Fos. 
Conclusions 
Inhibition of de-phosphorylation of eIF2 promotes 
differentiation and mineralization of osteoblasts through the 
upregulation of ATF4. The same inhibition in osteoclasts, on 
the other hand, suppresses osteoclastogenesis by 
downregulating RANKL-driven NFATc1. A genome-wide 
expression analysis demonstrates that the regulation of 
NFATc1 is mediated by c-Fos and JunB (Fig. 1). In summary, 
the current study demonstrates that inhibitors of 
de-phosphorylation of eIF2 such as salubrinal and 
guanabenz may provide a novel therapeutic possibility for 
bone diseases including osteoporosis. 
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